Drug General Information (ID: DDIWJECM03)
  Drug Name Carteolol (ophthalmic) Drug Info Amiodarone Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Antihypertensive Agents Antiarrhythmic Agents
  Structure

 Mechanism of Carteolol (ophthalmic)-Amiodarone Interaction (Severity Level: Moderate)
     Increased risk of atrioventricular block Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Carteolol (ophthalmic) Amiodarone
      Mechanism 1 Delay atrioventricular conduction Delay atrioventricular conduction
      Key Mechanism Factor 1
Factor Name Atrioventricular block
Factor Description Atrioventricular block is a type of cardiac conduction block that occurs when the electrical signal from the atria to the ventricles is impaired. In an Atrioventricular block, this electrical signal is either delayed or completely blocked. When the signal is completely blocked, the ventricles produce their own electrical signal to control the heart rate. The heart rate produced by the ventricles is much slower than that produced by the sinus node.
      Mechanism Description
  • Increased risk of atrioventricular block by the combination of Carteolol (ophthalmic) and Amiodarone 
     Increased risk of bradycardia Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Carteolol (ophthalmic) Amiodarone
      Mechanism 2 Bradycardia Bradycardia
      Key Mechanism Factor 2
Factor Name Bradycardia
Factor Description Bradycardia is a slow heart rate in which the heart beats less than 60 times per minute. If the heart rate is very slow and the heart is not pumping enough oxygen-rich blood to the body, and you may feel dizzy, very tired or weak, and short of breath.
      Mechanism Description
  • Increased risk of bradycardia by the combination of Carteolol (ophthalmic) and Amiodarone 

Recommended Action
      Management Clinical monitoring of patient hemodynamic status and response is recommended.

References
1 Leor J, Levartowsky D, Sharon C, Farfel Z "Amiodarone and beta-adrenergic blockers: an interaction with metoprolol but not with atenolol." Am Heart J 16 (1988): 206-7. [PMID: 3394625]
2 Ogunyankin KO, Singh BN "Mortality reduction by antiadrenergic modulation of arrhythmogenic substrate: Significance of combining beta blockers and amiodarone." Am J Cardiol 84 (1999): r76-82. [PMID: 10568664]
3 Boutitie F, Boissel JP, Connolly SJ, et al "Amiodarone interaction with beta-blockers - Analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases." Circulation 99 (1999): 2268-75. [PMID: 10226092]